Annovis Bio (NYSE:ANVS)
Annovis Bio (NYSE:ANVS) has stated that the first patient in a phase III study investigating the effectiveness of the company’s leading candidate, buntanetap, in the treatment of Parkinson’s Disease (PD) has been dosed with the investigational drug.
Back in October 2021, Annovis Bio announced the primary outcomes of its phase IIa research of buntanetap in Parkinson’s disease (PD) patients treated with multiple-dose cohorts of the drug once daily, ranging from 5 mg to 80 mg. According to the study’s findings, buntanetap is entirely risk-free and has no adverse effects on the test subjects.
In the phase IIa study, buntanetap revealed statistically significant improvements in motor dexterity, speed, and accuracy in early-to-moderate PD patients. The placebo-controlled group was given an inactive substance to take instead of the drug.
Following the positive results of the phase II study, the pharmaceutical company conferred with the FDA to discuss moving the medicine into its late-stage testing phase.
The FDA provided Annovis with encouraging feedback in December, allowing the company to move on with the phase III study of buntanetap in PD.
The late-stage trial is a randomized, double-blind, placebo-controlled evaluation of the safety, effectiveness, and tolerability of a 20mg dosage of buntanetap in 450 PD patients over a period of six months, in addition to the routine care procedure that these patients would normally receive.
In addition to Parkinson’s disease (PD), the translational inhibitor of neurotoxic proteins known as buntanetap is being tested for its potential efficacy in the treatment of Alzheimer’s disease (AD) and dementia in Down syndrome (AD-DS).
Following the news dissemination mentioned on August 24, the market price of Annovis Bio (NYSE:ANVS) stock increased by 5.88% during the trading hours of that day. When compared to the decline experienced by the industry as a whole, which was 21.6%, the loss suffered by Annovis shareholders was 35.5%.
The ABBV-951 product from AbbVie has been developed to provide Parkinson’s disease (PD) patients with the first continuous subcutaneous infusion of carbidopa/levodopa (CD/LD) prodrugs.
Featured Image: Megapixl @Adiruch
Author Shariq Khan 
